Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets

PLoS Computational Biology

Volumn 11, Issue 8, 2015, Pages

  Lu, Songjian ^a   Lu, Kevin N ^a   Cheng, Shi Yuan ^b   Hu, Bo ^b   Ma, Xiaojun ^a   Nystrom, Nicholas ^c   Lu, Xinghua ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c PITTSBURGH SUPERCOMPUTING CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTATIONAL COMPLEXITY; DISEASES; GENE EXPRESSION;

CANCER GENOMICS; CELLULAR SIGNALS; EXCLUSIVE SETS; GENE EXPRESSION DATA; GENOMIC ALTERATIONS; GENOMIC RESEARCH; MINIMUM WEIGHT; MUTUAL EXCLUSIVITIES; OBJECTIVE FUNCTIONS; SIGNALLING PATHWAYS;

TUMORS;

ARTICLE; CONTROLLED STUDY; DATA MINING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENOME ANALYSIS; GLIOBLASTOMA; HUMAN; INTRACELLULAR SIGNALING; MUTATIONAL ANALYSIS; NEOPLASM; OVARY TUMOR; SOMATIC GENOMIC ALTERATION; SOMATIC MUTATION; TRANSCRIPTOMICS; ALGORITHM; BIOLOGY; GENETICS; GENOME; MUTATION; PROCEDURES;

ALGORITHMS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOME; HUMANS; MUTATION; NEOPLASMS;

EID: 84940755892     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004257     Document Type: Article

References (63)

1. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57–70. 10647931
2. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674. doi: 10.1016/j.cell.2011.02.013 21376230
3. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr.et al. (2013) Cancer genome landscapes. Science 339: 1546–1558. doi: 10.1126/science.1235122 23539594
4. The Cancer Genome Atlas Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061–1068. doi: 10.1038/nature07385 18772890
5. The Cancer Genome Atlas Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609–615. doi: 10.1038/nature10166 21720365
6. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069–1075. doi: 10.1038/nature07423 18948947
7. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, et al. (2012) MuSiC: identifying mutational significance in cancer genomes. Genome Res 22: 1589–1598. doi: 10.1101/gr.134635.111 22759861
8. Hahn WC, Weinberg RA, (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2: 331–341. 12044009
9. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, et al. (2005) Reverse engineering of regulatory networks in human B cells. Nat Genet 37: 382–390. 15778709
10. Vandin F, Upfal E, Raphael BJ, (2011) Algorithms for detecting significantly mutated pathways in cancer. J Comput Biol 18: 507–522. doi: 10.1089/cmb.2010.0265 21385051
11. Vandin F, Clay P, Upfal E, Raphael BJ (2012) Discovery of mutated subnetworks associated with clinical data in cancer. Pac Symp Biocomput: 55–66.
12. Miller CA, Settle SH, Sulman EP, Aldape KD, Milosavljevic A, (2011) Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. BMC Med Genomics 4: 34. doi: 10.1186/1755-8794-4-34 21489305
13. Ciriello G, Cerami E, Sander C, Schultz N, (2012) Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 22: 398–406. doi: 10.1101/gr.125567.111 21908773
14. Zhao J, Zhang S, Wu LY, Zhang XS, (2012) Efficient methods for identifying mutated driver pathways in cancer. Bioinformatics 28: 2940–2947. doi: 10.1093/bioinformatics/bts564 22982574
15. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, et al. (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68: 6913–6921. doi: 10.1158/0008-5472.CAN-07-5084 18757405
16. Vandin F, Upfal E, Raphael BJ, (2012) De novo discovery of mutated driver pathways in cancer. Genome Res 22: 375–385. doi: 10.1101/gr.120477.111 21653252
17. Leiserson MD, Blokh D, Sharan R, Raphael BJ, (2013) Simultaneous identification of multiple driver pathways in cancer. PLoS Comput Biol 9: e1003054. doi: 10.1371/journal.pcbi.1003054 23717195
18. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25–29. 10802651
19. Chen V, Lu X (2013) Conceptualization of molecular findings by mining gene annotations. BMC Proceedings Accepted.
20. Jin B, Lu X, (2010) Identifying informative subsets of the Gene Ontology with information bottleneck methods. Bioinformatics 26: 2445–2451. doi: 10.1093/bioinformatics/btq449 20702400
21. Lu S, Jin B, Cowart LA, Lu X, (2013) From data towards knowledge: revealing the architecture of signaling systems by unifying knowledge mining and data mining of systematic perturbation data. PLoS One 8: e61134. doi: 10.1371/journal.pone.0061134 23637789
22. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, et al. (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12: R41. doi: 10.1186/gb-2011-12-4-r41 21527027
23. Ulitsky I, Krishnamurthy A, Karp RM, Shamir R, (2010) DEGAS: de novo discovery of dysregulated pathways in human diseases. PLoS One 5: e13367. doi: 10.1371/journal.pone.0013367 20976054
24. Kim YA, Wuchty S, Przytycka TM, (2011) Identifying causal genes and dysregulated pathways in complex diseases. PLoS Comput Biol 7: e1001095. doi: 10.1371/journal.pcbi.1001095 21390271
25. Kim YA, Salari R, Wuchty S, Przytycka TM (2013) Module cover—a new approach to genotype-phenotype studies. Pac Symp Biocomput: 135–146.
26. Karp RM, Miller R., Thatcher J., (1972) Reducibility Among Combinatorial Problems: In Complexity of Computer Computations, Plenum Press, New York.
27. Rice JA, (2007) Mathematical Statistics and Data Analysis: Duxbury Press.
28. Lu S, Lu X (2014) An exact algorithm for the weighed mutually exclusive maximum set cover problem. arXiv:14016385.
29. Downey RG, Fellows MR, (1999) Parameterized complexity. New York: Springer. xv, 533 p. p.
30. Lu S (2009) Randomized and deterministic parameterized algorithms and their applications in bioinformatics [Ph.D. dissertation]: Texas A&M University.
31. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, et al. (2003) Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 9: 1420–1426. 12684414
32. Landen CN, Jr.Lin YG, Immaneni A, Deavers MT, Merritt WM, et al. (2007) Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 13: 4098–4104. 17634535
33. Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, et al. (2013) Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochem Biophys Res Commun 436: 660–665. doi: 10.1016/j.bbrc.2013.06.012 23764397
34. Rath O, Kozielski F, (2012) Kinesins and cancer. Nat Rev Cancer 12: 527–539. doi: 10.1038/nrc3310 22825217
35. Shubbar E, Kovacs A, Hajizadeh S, Parris TZ, Nemes S, et al. (2013) Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer 13: 1. doi: 10.1186/1471-2407-13-1 23282137
36. Fu LJ, Wang B, (2013) Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis. J Ovarian Res 6: 92. doi: 10.1186/1757-2215-6-92 24341673
37. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature: 1–7.
38. Lu S, Cai C, Osmanbeyoglu HU, Chen L, Day R, et al. (2012) Identify Informative Modular Features for Predicting Cancer Clinical Outcomes
39. Puri S, Bachert C, Fimmel CJ, Linstedt AD, (2002) Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption. Traffic 3: 641–653. 12191016
40. Gemmill RM, Bemis LT, Lee JP, Sozen MA, Baron A, et al. (2002) The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway. Oncogene 21: 3507–3516. 12032852
41. Kosari F, Cheville JC, Ida CM, Karnes RJ, Leontovich AA, et al. (2012) Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer. Am J Pathol 181: 34–42. doi: 10.1016/j.ajpath.2012.03.043 22640805
42. Chen Y, Hao J, Jiang W, He T, Zhang X, et al. (2013) Identifying potential cancer driver genes by genomic data integration. Sci Rep 3: 3538. doi: 10.1038/srep03538 24346768
43. Beckner M SR, Flowers A, Katira K, D’Souza D, Patil S, Patel R, Nordberg M, Nanda A, (2011) Total copy number for 19 amplified genes in atypical/aggressive meningiomas correlates inversely with patient age. The FASEB Journal 25.
44. Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, et al. (2012) Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS One 7: e34414. doi: 10.1371/journal.pone.0034414 22509301
45. Burke JR, Hura GL, Rubin SM, (2012) Structures of inactive retinoblastoma protein reveal multiple mechanisms for cell cycle control. Genes Dev 26: 1156–1166. doi: 10.1101/gad.189837.112 22569856
46. Juan G, Cordon-Cardo C, (2001) Intranuclear compartmentalization of cyclin E during the cell cycle: disruption of the nucleoplasm-nucleolar shuttling of cyclin E in bladder cancer. Cancer Res 61: 1220–1226. 11221854
47. Dang CV, (2012) MYC on the path to cancer. Cell 149: 22–35. doi: 10.1016/j.cell.2012.03.003 22464321
48. Chu IM, Hengst L, Slingerland JM, (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8: 253–267. doi: 10.1038/nrc2347 18354415
49. Kaelin WG, Jr. (2002) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2: 673–682. 12209156
50. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, et al. (2013) Pan-cancer patterns of somatic copy number alteration. Nat Genet 45: 1134–1140. doi: 10.1038/ng.2760 24071852
51. Zhao Y, Yu H, Hu W, (2014) The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin (Shanghai) 46: 180–189. doi: 10.1093/abbs/gmt147 24389645
52. Wang H, Zeng X, Oliver P, Le LP, Chen J, et al. (1999) MDM2 oncogene as a target for cancer therapy: An antisense approach. Int J Oncol 15: 653–660. 10493945
53. Wade M, Li YC, Wahl GM, (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13: 83–96. doi: 10.1038/nrc3430 23303139
54. Ray RM, Bhattacharya S, Johnson LR, (2011) Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis 16: 35–44. doi: 10.1007/s10495-010-0538-0 20812030
55. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, et al. (2005) MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106: 3150–3159. 16014563
56. Costa B, Bendinelli S, Gabelloni P, Da Pozzo E, Daniele S, et al. (2013) Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS One 8: e72281. doi: 10.1371/journal.pone.0072281 23977270
57. Listernick R, Charrow J, Gutmann DH, (1999) Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 89: 38–44. 10469435
58. Parrinello S, Lloyd AC, (2009) Neurofibroma development in NF1—insights into tumour initiation. Trends Cell Biol 19: 395–403. doi: 10.1016/j.tcb.2009.05.003 19615906
59. Shapira S, Barkan B, Friedman E, Kloog Y, Stein R, (2007) The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ 14: 895–906. 17096025
60. Pina C, May G, Soneji S, Hong D, Enver T, (2008) MLLT3 regulates early human erythroid and megakaryocytic cell fate. Cell Stem Cell 2: 264–273. doi: 10.1016/j.stem.2008.01.013 18371451
61. Fuentealba RA, Liu Q, Kanekiyo T, Zhang J, Bu G, (2009) Low density lipoprotein receptor-related protein 1 promotes anti-apoptotic signaling in neurons by activating Akt survival pathway. J Biol Chem 284: 34045–34053. doi: 10.1074/jbc.M109.021030 19815552
62. Yahiro K, Satoh M, Nakano M, Hisatsune J, Isomoto H, et al. (2012) Low-density lipoprotein receptor-related protein-1 (LRP1) mediates autophagy and apoptosis caused by Helicobacter pylori VacA. J Biol Chem 287: 31104–31115. doi: 10.1074/jbc.M112.387498 22822085
63. Cover TM, Thomas JA, (2006) Elements of Information Theory: Wiley-Interscience.